Key Developments: MRI Interventions Inc (MRIC.OB)

MRIC.OB on OTC BB

1.05USD
23 Oct 2014
Price Change (% chg)

$0.00 (+0.19%)
Prev Close
$1.05
Open
--
Day's High
--
Day's Low
--
Volume
1,800
Avg. Vol
59,023
52-wk High
$1.75
52-wk Low
$0.65

Search Stocks

Latest Key Developments (Source: Significant Developments)

MRI Interventions Inc gives Q3 2014 revenue guidance below analysts' estimates
Monday, 6 Oct 2014 08:30am EDT 

MRI Interventions Inc:Estimates Q3 2014 total revenues at about $630,000.Q3 2014 revenue of $1.22 million - Thomson Reuters I/B/E/S.  Full Article

MRI Interventions Inc announces management changes
Thursday, 11 Sep 2014 09:00am EDT 

MRI Interventions Inc:Appoints Frank Grillo as the company's new Chief Executive Officer effective Jan. 1, 2015 and as President effective Oct. 6.Says Kimble Jenkins will assume the position of Executive Chairman on Jan. 1 2015.  Full Article

MRI Interventions Inc secures commitments for $3.55 mln in private notes offering
Monday, 10 Mar 2014 08:10am EDT 

MRI Interventions Inc:Enters into purchase agreement with certain accredited investors for private placement of securities.MRI Interventions will receive gross proceeds of $3,550,000.Securities being sold by company consist of 12 pct second-priority secured non-convertible promissory notes due 2019.Warrants to purchase 0.3 share of MRI Interventions' common stock for each dollar in principal amount of notes sold by the company, such warrants having exercise price of $1.75 per share.  Full Article

MRI Interventions Inc and Siemens enter into agreement to commercialize next generation software platform
Monday, 24 Feb 2014 08:00am EST 

MRI Interventions Inc Siemens Healthcare:Agreement to co-develop and commercialize next generation software platform that will enable minimally invasive catheter-based procedures to be performed under real-time magnetic resonance imaging (MRI) guidance.  Full Article

MRI Interventions Inc Raises FY 2013 Revenue Guidance
Tuesday, 12 Nov 2013 04:00pm EST 

MRI Interventions Inc announced that it is updating its guidance to increase both the lower and upper ends of the range of total product revenues the Company expects for fiscal 2013. The Company now anticipates total product revenues for fiscal 2013 of $2.5 million to $2.8 million, which would equate to total annual revenues for 2013 of $3.5 million to $3.8 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $3.3 million for fiscal 2013.  Full Article

MRI Interventions Inc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates
Tuesday, 13 Aug 2013 04:00pm EDT 

MRI Interventions Inc announced that the Company anticipates total product revenues for fiscal 2013 of $2.3 million to $2.7 million, which would equate to total annual revenues for fiscal 2013 of $3.2 million to $3.6 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $3.4 million for fiscal 2013.  Full Article

MRI Interventions Inc's ClearPoint System Helps Advance Brain Cancer Clinical Trial of investigational Gene Therapy Drug Toca 511, Demonstrates Benefits Of MRI-Guided Drug Delivery
Thursday, 25 Apr 2013 08:01am EDT 

MRI Interventions Inc announced that its ClearPoint Neuro Intervention System is advancing the minimally-invasive precision delivery of the investigational gene therapy drug Toca 511 into malignant brain tumors. The procedure is being performed under real-time visualization and direct magnetic resonance imaging (MRI) guidance at select clinical trial sites. Highlights of the ClearPoint System's application in the Toca 511 trial include: Improved flow rates during drug delivery. The recently-introduced SmartFlow large-bore cannula increases the drug delivery rate threefold over documented flow rates of the original SmartFlow cannula. Like the original SmartFlow cannula, the new cannula incorporates a stepped tip design to prevent reflux and leakage of the drug outside of the target area, but the new cannula's large bore allows for a clinically meaningful increased rate of delivery. Precise delivery of the therapeutic agent into the brain tumor. Direct visualization of the procedure in real-time allows surgeons to monitor and confirm delivery to the tumor of Toca 511 mixed with MRI contrast agent at the time of infusion. Multiple trajectories in a single case. The ClearPoint System includes a SmartFrame targeting device that works with software to allow convenient repositioning of the cannula for multiple trajectories in a single case, and an adjustable head stabilization device that accommodates a wide range of possible entry points.  Full Article

Search Stocks